HC Wainwright Has Bullish Forecast for DRUG Q2 Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Analysts at HC Wainwright increased their Q2 2026 earnings estimates for Bright Minds Biosciences in a report issued on Wednesday, March 4th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($1.20) per share for the quarter, up from their previous forecast of ($1.54). HC Wainwright has a “Buy” rating and a $145.00 price target on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Bright Minds Biosciences’ Q3 2026 earnings at ($1.74) EPS, Q4 2026 earnings at ($2.21) EPS, FY2026 earnings at ($6.19) EPS, Q1 2027 earnings at ($2.14) EPS, Q2 2027 earnings at ($2.35) EPS, Q3 2027 earnings at ($2.27) EPS, Q4 2027 earnings at ($2.44) EPS, FY2027 earnings at ($9.22) EPS, FY2028 earnings at ($8.12) EPS, FY2029 earnings at ($3.94) EPS and FY2030 earnings at $3.51 EPS.

Bright Minds Biosciences (NASDAQ:DRUG) last released its earnings results on Thursday, February 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.28.

Several other brokerages also recently commented on DRUG. Wall Street Zen downgraded Bright Minds Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Zacks Research lowered Bright Minds Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 2nd. Robert W. Baird set a $126.00 price objective on Bright Minds Biosciences in a research note on Friday, February 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bright Minds Biosciences in a research report on Monday, December 1st. Finally, Chardan Capital reissued a “buy” rating and issued a $80.00 price target on shares of Bright Minds Biosciences in a research report on Friday, January 2nd. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $124.50.

Bright Minds Biosciences Stock Down 1.9%

NASDAQ:DRUG opened at $77.80 on Friday. Bright Minds Biosciences has a twelve month low of $23.17 and a twelve month high of $123.75. The company has a fifty day moving average of $82.97 and a 200-day moving average of $67.66. The firm has a market capitalization of $756.99 million, a P/E ratio of -40.31 and a beta of -6.04.

Institutional Trading of Bright Minds Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC boosted its stake in Bright Minds Biosciences by 0.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,155,995 shares of the company’s stock valued at $90,832,000 after buying an additional 10,335 shares during the period. Sio Capital Management LLC grew its holdings in shares of Bright Minds Biosciences by 0.9% during the second quarter. Sio Capital Management LLC now owns 512,338 shares of the company’s stock worth $13,377,000 after purchasing an additional 4,776 shares in the last quarter. Vivo Capital LLC raised its stake in Bright Minds Biosciences by 99.4% in the third quarter. Vivo Capital LLC now owns 501,617 shares of the company’s stock valued at $30,428,000 after purchasing an additional 250,045 shares in the last quarter. Braidwell LP grew its stake in Bright Minds Biosciences by 6.8% in the 4th quarter. Braidwell LP now owns 324,358 shares of the company’s stock worth $25,313,000 after buying an additional 20,673 shares in the last quarter. Finally, MPM Bioimpact LLC bought a new position in shares of Bright Minds Biosciences in the 4th quarter worth $17,961,000. Institutional investors own 40.52% of the company’s stock.

More Bright Minds Biosciences News

Here are the key news stories impacting Bright Minds Biosciences this week:

• Positive Sentiment: HC Wainwright raised its price target to $145 (from $115) and kept a “Buy” rating, signaling continued analyst conviction and meaningful upside vs. the current share level. Benzinga: HC Wainwright price target raise
• Positive Sentiment: The firm materially increased its long‑term outlook: FY2030 EPS was raised to $3.51 (from $2.24), implying improved profitability expectations out over the cycle if product/clinical milestones succeed. MarketBeat: Analyst model changes
• Positive Sentiment: Near‑term quarterly estimates were upgraded in places — notably Q2 2026 (to -$1.20 from -$1.54), Q3 2026 (to -$1.74 from -$1.91) and a small improvement to Q4 2026 — and HC Wainwright lifted its FY2026 view (to -$6.19 from -$6.94), which reduces near‑term downside risk relative to prior estimates. MarketBeat: Quarterly estimate changes
• Neutral Sentiment: Reported short interest entries show zero shares and NaN changes — this appears to be a data/reporting anomaly and does not provide a reliable signal about bearish positioning. Investors should rely on confirmed short‑interest releases for clarity. MarketBeat: Short interest data
• Negative Sentiment: HC Wainwright trimmed multiple 2027 quarter forecasts (Q1–Q4 2027 revisions) and cut FY2027 to -$9.22 (from -$8.75), and lowered FY2029 estimates — signaling the analyst sees heavier losses or slower commercialization/scale in the mid term, which increases execution risk and could weigh on the stock if clinical/cash milestones slip. MarketBeat: 2027/2029 estimate cuts

About Bright Minds Biosciences

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.